Creo Medical Group PLC on Wednesday said its Speedboat UltraSlim device has been used successfully in Latin America for the first time.
The Chepstow, Wales-based medical device company focused on surgical endoscopy said the device was used at the Ecuadorian Institute of Digestive Diseases in December, with 12 procedures having been performed by a Creo medical team over a three-day period.
The company said the team also performed the first F-Poem procedure with the device. F-Poem, which refers to endoscopic fundoplication peroral endoscopic myotomy, is a ‘minimally invasive endoscopic procedure used to treat oesophageal motility disorders in patients who are prone to gastroesophageal reflux.’
Creo noted that the product has been used in multiple procedures in the UK and US since its limited release in December.
Chief Executive Craig Gulliford said: ‘The procedures done at IECED have shown the full potential of the new Speedboat UltraSlim. We were thrilled to witness the successful execution of the F-Poem procedure using solely the Speedboat device, a task that traditionally requires three separate instruments. This not only showcases the device’s efficiency but also enhances the cost-effectiveness of the procedure, underscoring the economic advantages Creo’s technology can deliver to our valued customers.’
Michael Kahaleh, who performed many of the procedures at IECED, said: ‘Once you have acquired the knowledge to use this technology, you’re really going to save procedure time. The technology allows the endoscopist to complete an F-Poem procedure with a single device, whereas previously it required three different devices.’
Creo Medical shares rose 2.2% to 44.98 pence each on Wednesday afternoon in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
